Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 315-318

  Spina, E ^a   Avenoso, A ^a   Campo, G M ^a   Scordo, M G ^a   Caputi, A P ^a   Perucca, E ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

CYP2D6; CYP3A4; desipramine; drug interaction; imipramine; ketoconazole

Indexed keywords

2 HYDROXYIMIPRAMINE; DESIPRAMINE; DRUG METABOLITE; IMIPRAMINE; KETOCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0031057666     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00539.x     Document Type: Article

References (28)

1. Furlanut M, Benetello P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin Pharmacokinet 1993; 24: 301-318.
2. Spina E, Birgersson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984; 36: 677-682.
3. Brosen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986; 40: 543-549.
4. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalysed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827-832.
5. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Meth 1994; 31: 177-186.
6. Skjelbo E, Brosen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49: 18-23.
7. Chiba C, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4′hydroxylase on imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994; 34: 237-242.
8. Spina E, Perucca E. Newer and older antidepressants: A comparative review of drug interactions. CNS Drugs 1994; 2: 479-497.
9. Brosen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1989; 37: 155-160.
10. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-246.
11. Brosen K, Skielbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
12. Levy RH, Wurden CJ. Carbamazepine. Interactions with other drugs. In Antiepileptic drugs. Fourth Edition, eds Levy RH, Mattson RH, Meldram BS, New York: Raven Press, 1995: 543-553.
13. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 1995; 117: 413-416.
14. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996; 18: 60-64.
15. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986; 22: 49-53.
16. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-626.
17. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P. Effect of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
18. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985; 38: 618-624.
19. Sutfin TA, Jusko WJ. High-performance liquid cromatography assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci 1979; 68: 703-705.
20. Riley CM, James MO. Determination of ketoconazole in plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J Chromatogr 1986; 377: 287-294.
21. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-19.
22. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 221: 511-526.
23. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-151.
24. Olkkola KT, Backman J, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
25. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
26. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268 :1278-1283.
27. Perucca E, Richens A. Biotransformation. In: Antiepileptic drugs, Fourth Edition, eds Levy RH, Mattson RH, Meldrum BS, New York: Raven Press, 1995: 31-50.
28. Gannon RH, Anderson ML. Fluconazole-nortriptyline drug interaction. Ann Phamacother 1992; 26: 1456-1457.